CryoLife Continues to Add Expertise to Company's Board of Directors.

ATLANTA--(BW HealthWire)--Sept. 16, 1999--

CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has added Alexander C. ("Sandy") Schwartz, Jr., age 67, to the Company's Board of Directors, increasing the number of members serving on the Board of Directors to eight.

Mr. Schwartz retired from Prudential Securities in 1996 after 33 years of service. While at Prudential Securities he held various positions including co-head of the Investment Banking Division, Managing Director of the firm's International Division and Managing Director of the Health Care Group. Mr. Schwartz is a graduate of Columbia University and has served on the Board of Directors of several public and privately held companies.

Steven G. Anderson, President and Chief Executive Officer of CryoLife, said, "Recently, we have been very fortunate to add experienced members from diverse business backgrounds to our Board of Directors. Mr. Schwartz, the third person to join our Board in the last six weeks, adds an impressive background in investment banking, specifically in the area of international healthcare. He is an excellent complement to our newest additions to the Board, John Cook, Chairman and Chief Executive Officer of The Profit Recovery Group International, Inc., and Bruce Van Dyne, M.D., a board-certified neurologist. We feel very fortunate to have experienced corporate executives and physicians managing our growing, international healthcare company."

Founded in 1984, CryoLife, Inc. is the leader in the development and commercialization of living human tissue implantable devices for use in cardiovascular, vascular and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive, CE marked in the European Union for use in vascular and pulmonary sealing and repair, is distributed throughout Europe. The Company also manufactures CryoLife-O'Brien(R) and CryoLife-Ross(TM) stentless porcine heart valves which are distributed within the European Community.

Statements made in this press Release which look forward in time involve risks and uncertainties and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such risks and uncertainties include changes in economic cycles, competition from other companies, changes in laws and governmental regulations applicable to the Company and other risk factors detailed in the Company's Securities and Exchange Commission filings, including the Company's Form 10-K for the year ended December 31, 1998.

The Company web site is: http://www.cryolife.com

Editor's Note:

CryoLife Customer Service may be accessed by telephone:

800/438-8285 (U.S. and Canada)

770/419-3355 (International)

770/590-3753 (International fax)

E-mail: [e-mail]